公开(公告)号：WO2003004601A2

公开(公告)日：2003-01-16

申请号：PCT/US2002/020599

申请日：2002-06-28

Applicant: BIOLNCEPT, INC

Inventor： BARNEA, Eytan ,  PEREZ, RUBEN RENEE GONZALEZ ,  LEAVIS, Paul, C.

IPC: C12N

CPC classification number: C07K7/06 ,  C07K14/4715 ,  G01N33/689 ,  G01N2333/70507

Abstract: The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytomery assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled antilymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (I) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Abstract translation: 本发明涉及用于检测PIF存在的分析方法，以及使用该分析鉴定的PIF肽。 具体而言，本发明涉及用于检测PIF的流式细胞分析。 它至少部分基于以下观察结果：使用荧光标记的抗淋巴细胞和抗血小板抗体的流式细胞术显示在PIF存在下玫瑰花结形成增加。 进一步基于流式细胞术证实在PIF存在下单克隆抗体与CD2结合减少的观察结果。 本发明进一步涉及当加入到Jurkat细胞培养物中时观察到（I）减少抗CD2抗体与Jurkat细胞结合的PIF肽; （ii）增加Jurkat细胞中CD2的表达; 或（iii）降低Jurkat细胞活力。 在另外的实施方案中，本发明提供了通过确定测试样品对抗CD2抗体与CD2底物的结合的影响来检测PIF的ELISA测定。

公开(公告)号：WO0232953A3

公开(公告)日：2003-01-09

申请号：PCT/DK0100695

申请日：2001-10-19

Applicant: COMO BIOTECH APS ,  OXVIG CLAUS ,  OVERGAARD MICHAEL TOFT

Inventor： OXVIG CLAUS ,  OVERGAARD MICHAEL TOFT

IPC: A01K67/027 ,  A61K31/7088 ,  A61K35/12 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K16/40 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N15/09 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/37 ,  C12Q1/68 ,  G01N21/77 ,  G01N21/78 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/577 ,  G01N33/68

CPC classification number: C12N9/6489 ,  A61K38/00 ,  C07K14/4715 ,  C07K2319/21 ,  C07K2319/41 ,  C12Q1/37 ,  C12Q1/6876 ,  G01N33/689 ,  G01N2333/96486 ,  G01N2500/02

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, use of the protein to produce antibodies capable of binding specifically to the protein, methods for screening for pathologies in pregnant and non-pregnant patients that are based on detection of PAPP-A2 antigen in human body fluids or PAPP-A2-encoding nucleic acid molecules, use of the protein to screen for agents that alter the protease activity of PAPP-A2, use of the protein as a therapeutic target for such agents, and use of the protein as a therapeutic agent in relevant pathological states. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described. The present invention also provides the identification of a natural substrate of PAPP-A2, insulin-like growth factor binding protein (IGFBP)-5.

Abstract translation: 本发明提供鉴定并编码与妊娠相关血浆蛋白-A（PAPP-A）具有同源性的新蛋白质的核苷酸和氨基酸序列。 我们表示这种蛋白质PAPP-A2。 编码PAPP-A2的cDNA源自人胎盘。 本发明还提供编码PAPP-A2的核苷酸序列的反义分子，产生纯化的PAPP-A2的表达载体，能够特异性结合PAPP-A2的抗体，用于检测PAPP-A2的杂交探针或寡核苷酸 编码核苷酸序列，用于表达PAPP-A2的遗传工程改造的宿主细胞，使用蛋白质产生能够特异性结合蛋白质的抗体，用于筛选怀孕和非怀孕患者的病理学的方法，所述方法基于检测 PAPP-A2抗原在人体液或PAPP-A2编码核酸分子中的用途，使用该蛋白筛选改变PAPP-A2的蛋白酶活性的试剂，使用该蛋白作为该试剂的治疗靶标，并使用 的蛋白质作为相关病理状态下的治疗剂。 还描述了用于筛选怀孕和/或非怀孕患者中改变的局灶增生状态的方法，其包括检测PAPP-A2的水平。 本发明还提供PAPP-A2，胰岛素样生长因子结合蛋白（IGFBP）-5的天然底物的鉴定。

公开(公告)号：WO0158922A9

公开(公告)日：2002-10-17

申请号：PCT/US0104539

申请日：2001-02-12

Applicant: UNIV CALIFORNIA ,  ECONOMOU JAMES S ,  BUTTERFIELD LISA H ,  RIBAS BRUGUERA ANTONI

Inventor： ECONOMOU JAMES S ,  BUTTERFIELD LISA H ,  RIBAS BRUGUERA ANTONI

IPC: C12N15/00 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  A61K39/39 ,  A61P1/16 ,  A61P35/00 ,  A61P37/04 ,  C07K14/47 ,  C07K14/82 ,  A61K38/04 ,  A61K45/00 ,  A61K48/00 ,  C07H21/04 ,  C07K2/00 ,  C07K4/12 ,  C07K7/06 ,  C12N5/08 ,  C12N15/11

CPC classification number: C07K14/4715 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158

Abstract: A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule, where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells. A composition for preventing or for treating cancer comprising a peptide having at least part of the sequence of alpha fetoprotein.

Abstract translation: 一种用于预防或治疗哺乳动物中的癌症的方法，其中所述癌细胞在细胞表面表达至少一部分甲胎蛋白分子，所述方法包括在所述哺乳动物中产生免疫应答至少部分 α-甲胎蛋白分子的氨基酸序列，其中免疫应答包括激活针对癌细胞的甲胎蛋白肽特异性T淋巴细胞。 一种用于预防或治疗癌症的组合物，其包含具有至少部分甲胎蛋白序列的肽。

公开(公告)号：WO02044734A1

公开(公告)日：2002-06-06

申请号：PCT/EP2001/013876

申请日：2001-11-28

IPC: A61K31/7052 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K14/4715 ,  C07K16/18 ,  G01N33/574

Abstract: The present invention relates to a method for diagnosing a tumor in a patient said method comprising measuring the concentration of Progesterone-Induced Immunomodulatory Protein (PIBF) or a derivative thereof or a fragment thereof in the sample taken from the patient, and to the use of an anti-PIBF antibody, PIBF or a derivative thereof or a fragment thereof, and a polynucleotide encoding PIBF, respectively, as an anti-tumor medicine.

Abstract translation: 本发明涉及一种用于诊断患者肿瘤的方法，所述方法包括测量取自患者的样品中孕激素诱导的免疫调节蛋白（PIBF）或其衍生物或其片段的浓度，以及使用 抗PIBF抗体，PIBF或其衍生物或其片段，以及分别编码PIBF的多核苷酸作为抗肿瘤药物。

公开(公告)号：WO01094386A2

公开(公告)日：2001-12-13

申请号：PCT/EP2001/006518

申请日：2001-06-08

IPC: A23L3/3526 ,  A23L33/18 ,  A61K38/00 ,  C07K14/47 ,  C07K14/00

CPC classification number: A23L3/3526 ,  A23L33/18 ,  A61K38/00 ,  C07K14/47 ,  C07K14/4715 ,  C07K14/4723

Abstract: The invention relates to antibiotically effective peptides, which are purified out of human and animal tissue extracts for the purpose of medically and commercially using them as medicaments. The peptides can be proteolytically produced by using biotechnological and recombinant methods, chemical synthesis, and from corresponding precursor proteins. The antibiotically effective peptides can be used in a suitable galenic preparation as medicaments/animal medicaments and foodstuff additives.

Abstract translation: 本发明涉及抗生素肽为来自人及动物组织提取物的医药产品医疗和工业使用的目的进行纯化。 肽可以通过蛋白水解通过生物技术和重组方法或化学合成，以及从对应的前体蛋白而制备。 抗生素肽可以用作药物/兽药和食品添加剂以合适的药物制剂。

公开(公告)号：WO9839465A3

公开(公告)日：1998-12-10

申请号：PCT/US9804084

申请日：1998-03-03

Applicant: CALYDON INC ,  LITTLE ANDREW S ,  LAMPARSKI HENRY G ,  HENDERSON DANIEL R ,  SCHUUR ERIC R

Inventor： LITTLE ANDREW S ,  LAMPARSKI HENRY G ,  HENDERSON DANIEL R ,  SCHUUR ERIC R

IPC: C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61K47/48 ,  A61K48/00 ,  A61P35/00 ,  C07K14/075 ,  C07K14/47 ,  C12N5/10 ,  C12N7/00 ,  C12N15/63 ,  C12N15/861 ,  C12Q1/02 ,  C12N15/86

CPC classification number: C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K14/4715 ,  C12N15/63 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/002 ,  C12N2830/008

Abstract: Adenovirus vectors replication specific for cells expressing α-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

公开(公告)号：WO98035028A3

公开(公告)日：1998-10-22

申请号：PCT/US1998/001301

申请日：1998-01-23

IPC: C12N15/09 ,  A61K35/76 ,  A61K35/761 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/47 ,  C12N15/861 ,  C12N15/00

CPC classification number: C12N7/00 ,  A61K35/761 ,  A61K38/1774 ,  A61K38/217 ,  A61K48/00 ,  C07K14/4715 ,  C12N15/86 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/60 ,  C12N2840/20 ,  A61K2300/00

Abstract: This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.

公开(公告)号：WO98039465A2

公开(公告)日：1998-09-11

申请号：PCT/US1998/004084

申请日：1998-03-03

IPC: C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61K47/48 ,  A61K48/00 ,  A61P35/00 ,  C07K14/075 ,  C07K14/47 ,  C12N5/10 ,  C12N7/00 ,  C12N15/63 ,  C12N15/861 ,  C12Q1/02 ,  C12N15/86

CPC classification number: C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K14/4715 ,  C12N15/63 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/002 ,  C12N2830/008

Abstract: Adenovirus vectors replication specific for cells expressing alpha -fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

Abstract translation: 提供了对表达α-甲胎蛋白（AFP）的细胞特异性的腺病毒载体及其使用方法。 通过提供依赖于AFP表达的转录起始调节，病毒复制仅限于表达AFP的靶细胞，特别是肝细胞癌细胞。 腺病毒载体可用于检测和监测样品中是否存在产生AFP的细胞，以及杀死选择性产生AFP的恶性细胞。

公开(公告)号：WO1998000536A1

公开(公告)日：1998-01-08

申请号：PCT/GB1997001740

申请日：1997-06-26

Applicant: THE MINISTER OF AGRICULTURE, FISHERIES AND FOOD ,  TAUSSIG, Michael, John ,  SYMONS, Derek, Bryan, Alfred

Inventor： THE MINISTER OF AGRICULTURE, FISHERIES AND FOOD

IPC: C12N15/11

CPC classification number: A61K39/0006 ,  A61K2039/6081 ,  C07K14/4715 ,  C07K16/18

Abstract: The production of anti-sera to small peptides or polypeptides which cross react with uteroglobin is disclosed giving rise to diagnostic and detection as well as immunocontraceptive methods. In particular, a method for controlling the fertility of a female mammal, especially a feral mammal such as wild rabbits, is described. This method comprises administering to a mammal a peptide or polypeptide which stimulates an immune response, said response including production of elements which bind uteroglobin and reduce fertility of said female mammal. Peptides or polypeptides which may be used in the method include peptides or polypeptides comprising (a) uteroglobin or a fragment thereof, a peptide or polypeptide derived from uteroglobin, or a variant or peptide mimetic of any of these, and (b) a carrier protein. This may be applied in a conventional vaccine formulation, including using viral vaccine vectors. Preferably, they are formulated into compositions which are suitable for oral administration. Novel peptide or polypeptides for use in the method, their production and other aspects are also described and claimed.

Abstract translation: 公开了产生与血清蛋白交叉反应的小肽或多肽的抗血清，产生诊断和检测以及免疫避孕方法。 特别地，描述了一种用于控制雌性哺乳动物，特别是野生哺乳动物如野兔的生育力的方法。 该方法包括向哺乳动物施用刺激免疫应答的肽或多肽，所述应答包括结合所述雌性哺乳动物结合血红蛋白的元素的产生并降低其生育力。 可用于该方法的肽或多肽包括肽或多肽，其包含（a）子宫肌红蛋白或其片段，衍生自子宫红素的肽或多肽，或其中任何一种的变体或肽模拟物，和（b）载体蛋白 。 这可以应用于常规疫苗制剂中，包括使用病毒疫苗载体。 优选将它们配制成适于口服给药的组合物。 还描述和要求保护用于该方法，其生产和其它方面的新型肽或多肽。

公开(公告)号：WO1995015338A1

公开(公告)日：1995-06-08

申请号：PCT/AU1994000740

申请日：1994-11-30

Applicant: THE UNIVERSITY OF QUEENSLAND ,  MORTON, Halle ,  CAVANAGH, Alice, Christina

Inventor： THE UNIVERSITY OF QUEENSLAND

IPC: C07K14/47

CPC classification number: C07K14/4715 ,  A61K38/00 ,  C07K16/18

Abstract: A process for the detection of cpn10 in serum or other biological fluids including the steps of (i) raising antibody to cpn10; (ii) reacting said antibody with a sample of biological fluid suspected of containing cpn10; and (iii) detecting the presence of cpn10 in said sample by a signal amplification resulting from production of a cpn10-antibody complex. There is also provided a process for promotion of cell growth or immunosuppression including the step of administration of cpn10 to a mammalian subject. There is also provided recombinant cpn10 having the sequence GSAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVEAVGSGSKGKGGEIQPVSVKEGDKVLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD.

Abstract translation: 一种用于检测血清或其他生物液体中的cpn10的方法，包括以下步骤：（i）提高对cpn10的抗体; （ii）使所述抗体与疑似含有cpn10的生物流体样品反应; 和（iii）通过由产生cpn10抗体复合物产生的信号扩增来检测所述样品中cpn10的存在。 还提供了促进细胞生长或免疫抑制的方法，包括向哺乳动物受试者施用cpn10的步骤。 还提供了具有序列GSAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVEAVGSGSKGKGGEIQPVSVKEGDKVLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD的重组cpn10。